Clinical trial
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown…
NCT00430963 · Merz Pharmaceuticals GmbH, Industry · Completed
Key facts
| NCT number | NCT00430963 |
|---|---|
| Title | IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines |
| Official title | A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines |
| Lead sponsor | Merz Pharmaceuticals GmbH, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glabellar Frown Lines |
| Intervention type | Drug |
| Interventions | IncobotulinumtoxinA (Xeomin) (20 Units), Placebo |
| Enrollment | 256 |
| Start date | Oct 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Feb 2, 2007 |
| Last update posted | Oct 26, 2011 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: